O	0	1	A
O	2	12	Comparison
O	13	15	of
O	16	24	Proposed
B-intervention	25	35	Biosimilar
I-intervention	36	38	LA
I-intervention	38	39	-
I-intervention	39	45	EP2006
O	46	49	and
B-control	50	59	Reference
I-control	60	73	Pegfilgrastim
O	74	77	for
O	78	81	the
O	82	92	Prevention
O	93	95	of
B-condition	96	107	Neutropenia
O	108	110	in
O	111	119	Patients
O	120	124	With
O	125	130	Early
O	130	131	-
O	131	136	Stage
O	137	143	Breast
O	144	150	Cancer
O	151	160	Receiving
O	161	177	Myelosuppressive
O	178	186	Adjuvant
O	187	189	or
O	190	201	Neoadjuvant
O	202	214	Chemotherapy
O	214	215	:
O	216	229	Pegfilgrastim
O	230	240	Randomized
O	241	249	Oncology
O	250	251	(
O	251	261	Supportive
O	262	266	Care
O	266	267	)
O	268	273	Trial
O	274	276	to
O	277	285	Evaluate
O	286	297	Comparative
O	298	307	Treatment
O	308	309	(
O	309	316	PROTECT
O	316	317	-
O	317	318	2
O	318	319	)
O	319	320	,
O	321	322	a
O	323	328	Phase
O	329	332	III
O	332	333	,
O	334	344	Randomized
O	344	345	,
O	346	352	Double
O	352	353	-
O	353	358	Blind
O	359	364	Trial
O	364	365	.

O	366	379	Pegfilgrastim
O	380	382	is
O	383	389	widely
O	390	394	used
O	395	398	for
O	399	402	the
O	403	413	prevention
O	414	416	of
O	417	429	chemotherapy
O	429	430	-
O	430	437	induced
O	438	449	neutropenia
O	449	450	.

O	451	453	In
O	454	460	highly
O	461	470	regulated
O	471	478	markets
O	478	479	,
O	480	485	there
O	486	489	are
O	490	499	currently
O	500	502	no
O	503	511	approved
O	512	523	biosimilars
O	524	526	of
O	527	540	pegfilgrastim
O	540	541	.

O	542	555	Pegfilgrastim
O	556	566	Randomized
O	567	575	Oncology
O	576	577	(
O	577	587	Supportive
O	588	592	Care
O	592	593	)
O	594	599	Trial
O	600	602	to
O	603	611	Evaluate
O	612	623	Comparative
O	624	633	Treatment
O	634	635	(
O	635	642	PROTECT
O	642	643	-
O	643	644	2
O	644	645	)
O	646	649	was
O	650	651	a
O	652	664	confirmatory
O	665	673	efficacy
O	674	677	and
O	678	684	safety
O	685	690	study
O	691	699	designed
O	700	702	to
O	703	710	compare
O	711	719	proposed
O	720	730	biosimilar
O	731	733	LA
O	733	734	-
O	734	740	EP2006
O	741	745	with
O	746	755	reference
O	756	769	pegfilgrastim
O	770	771	(
O	771	779	Neulasta
O	779	780	,
O	781	786	Amgen
O	786	787	)
O	788	790	in
B-eligibility	791	796	early
I-eligibility	796	797	-
I-eligibility	797	802	stage
I-eligibility	803	809	breast
I-eligibility	810	816	cancer
I-eligibility	817	825	patients
I-eligibility	826	835	receiving
I-eligibility	836	844	adjuvant
I-eligibility	845	847	or
I-eligibility	848	859	neoadjuvant
I-eligibility	860	876	myelosuppressive
I-eligibility	877	889	chemotherapy
O	889	890	.

O	891	892	A
O	893	898	total
O	899	901	of
B-total-participants	902	905	308
O	906	914	patients
O	915	919	were
O	920	930	randomized
O	931	933	to
O	934	936	LA
O	936	937	-
O	937	943	EP2006
O	944	946	or
O	947	956	reference
O	957	970	pegfilgrastim
O	970	971	.

O	972	976	Each
O	977	984	patient
O	985	993	received
O	994	997	TAC
O	998	999	(
O	999	1010	intravenous
O	1011	1020	docetaxel
O	1021	1023	75
O	1024	1026	mg
O	1026	1027	/
O	1027	1028	m
O	1028	1029	(
O	1029	1030	2
O	1030	1031	)
O	1031	1032	,
O	1033	1044	doxorubicin
O	1045	1047	50
O	1048	1050	mg
O	1050	1051	/
O	1051	1052	m
O	1052	1053	(
O	1053	1054	2
O	1054	1055	)
O	1055	1056	,
O	1057	1060	and
O	1061	1077	cyclophosphamide
O	1078	1081	500
O	1082	1084	mg
O	1084	1085	/
O	1085	1086	m
O	1086	1087	(
O	1087	1088	2
O	1088	1089	)
O	1089	1090	)
O	1091	1093	on
O	1094	1097	day
O	1098	1099	1
O	1100	1102	of
O	1103	1107	each
O	1108	1113	cycle
O	1113	1114	,
O	1115	1118	for
O	1119	1122	six
O	1123	1125	or
O	1126	1130	more
O	1131	1137	cycles
O	1137	1138	.

O	1139	1152	Pegfilgrastim
O	1153	1154	(
O	1154	1156	LA
O	1156	1157	-
O	1157	1163	EP2006
O	1164	1166	or
O	1167	1176	reference
O	1176	1177	)
O	1178	1181	was
O	1182	1187	given
O	1188	1202	subcutaneously
O	1203	1204	(
O	1204	1205	6
O	1206	1208	mg
O	1209	1211	in
O	1212	1213	0
O	1213	1214	.
O	1214	1215	6
O	1216	1218	mL
O	1218	1219	)
O	1220	1222	on
O	1223	1226	day
O	1227	1228	2
O	1229	1231	of
O	1232	1236	each
O	1237	1242	cycle
O	1242	1243	.

O	1244	1247	The
O	1248	1255	primary
O	1256	1264	endpoint
O	1265	1268	was
B-outcome-Measure	1269	1277	duration
I-outcome-Measure	1278	1280	of
I-outcome-Measure	1281	1287	severe
I-outcome-Measure	1288	1299	neutropenia
I-outcome-Measure	1300	1301	(
I-outcome-Measure	1301	1304	DSN
I-outcome-Measure	1304	1305	)
I-outcome-Measure	1306	1312	during
I-outcome-Measure	1313	1318	cycle
I-outcome-Measure	1319	1320	1
O	1321	1322	(
O	1322	1328	number
O	1329	1331	of
O	1332	1343	consecutive
O	1344	1348	days
O	1349	1353	with
O	1354	1356	an
O	1357	1365	absolute
O	1366	1376	neutrophil
O	1377	1382	count
O	1383	1384	<
O	1384	1385	0
O	1385	1386	.
O	1386	1387	5
O	1388	1389	×
O	1390	1392	10
O	1392	1393	(
O	1393	1394	9
O	1394	1395	)
O	1395	1396	/
O	1396	1397	L
O	1397	1398	)
O	1398	1399	,
O	1400	1404	with
O	1405	1416	equivalence
O	1417	1426	confirmed
O	1427	1429	if
O	1430	1432	90
O	1432	1433	%
O	1434	1437	and
O	1438	1440	95
O	1440	1441	%
O	1442	1452	confidence
O	1453	1462	intervals
O	1463	1464	(
O	1464	1467	CIs
O	1467	1468	)
O	1469	1473	were
O	1474	1480	within
O	1481	1482	a
O	1483	1484	1
O	1484	1485	-
O	1485	1488	day
O	1489	1495	margin
O	1495	1496	.

O	1497	1505	Baseline
O	1506	1521	characteristics
O	1522	1526	were
O	1527	1531	well
O	1532	1540	balanced
O	1540	1541	.

B-outcome	1542	1545	DSN
O	1546	1549	was
O	1550	1560	equivalent
O	1561	1568	between
O	1569	1575	groups
O	1576	1578	at
O	1579	1583	mean
O	1584	1585	±
O	1586	1588	SD
O	1589	1590	1
O	1590	1591	.
O	1591	1593	36
O	1594	1595	±
O	1596	1597	1
O	1597	1598	.
O	1598	1600	13
O	1601	1602	(
O	1602	1604	LA
O	1604	1605	-
O	1605	1611	EP2006
O	1611	1612	,
O	1613	1614	n
O	1615	1616	=
B-intervention-participants	1617	1620	155
O	1620	1621	)
O	1622	1625	and
O	1626	1627	1
O	1627	1628	.
O	1628	1630	19
O	1631	1632	±
O	1633	1634	0
O	1634	1635	.
O	1635	1637	98
O	1638	1639	(
O	1639	1648	reference
O	1648	1649	,
O	1650	1651	n
O	1652	1653	=
B-control-participants	1654	1657	153
O	1657	1658	)
O	1659	1661	in
O	1662	1667	cycle
O	1668	1669	1
O	1669	1670	.

O	1671	1675	With
O	1676	1677	a
B-outcome	1678	1687	treatment
I-outcome	1688	1698	difference
O	1699	1700	(
O	1700	1709	reference
O	1710	1715	minus
O	1716	1718	LA
O	1718	1719	-
O	1719	1725	EP2006
O	1725	1726	)
O	1727	1729	of
O	1730	1731	-
O	1731	1732	0
O	1732	1733	.
O	1733	1735	16
O	1736	1740	days
O	1741	1742	(
O	1742	1744	90
O	1744	1745	%
O	1746	1748	CI
O	1749	1750	-
O	1750	1751	0
O	1751	1752	.
O	1752	1754	36
O	1755	1757	to
O	1758	1759	0
O	1759	1760	.
O	1760	1762	04
O	1762	1763	;
O	1764	1766	95
O	1766	1767	%
O	1768	1770	CI
O	1771	1772	-
O	1772	1773	0
O	1773	1774	.
O	1774	1776	40
O	1777	1779	to
O	1780	1781	0
O	1781	1782	.
O	1782	1784	08
O	1784	1785	)
O	1785	1786	,
O	1787	1789	LA
O	1789	1790	-
O	1790	1796	EP2006
O	1797	1800	was
O	1801	1811	equivalent
O	1812	1814	to
O	1815	1824	reference
O	1825	1838	pegfilgrastim
O	1838	1839	.

B-outcome	1840	1849	Secondary
I-outcome	1850	1858	efficacy
I-outcome	1859	1869	parameters
O	1870	1874	were
O	1875	1882	similar
O	1883	1890	between
O	1891	1897	groups
O	1898	1904	during
O	1905	1910	cycle
O	1911	1912	1
O	1913	1916	and
O	1917	1923	across
O	1924	1930	cycles
O	1930	1931	.

B-outcome	1932	1938	Safety
I-outcome	1939	1947	profiles
O	1948	1952	were
O	1953	1957	also
O	1958	1965	similar
O	1966	1973	between
O	1974	1980	groups
O	1980	1981	.

B-outcome	1982	1984	No
I-outcome	1985	1997	neutralizing
I-outcome	1998	2008	antibodies
O	2009	2016	against
O	2017	2030	pegfilgrastim
O	2030	2031	,
O	2032	2042	filgrastim
O	2042	2043	,
O	2044	2046	or
O	2047	2059	polyethylene
O	2060	2066	glycol
O	2067	2071	were
O	2072	2080	detected
O	2080	2081	.

O	2082	2084	LA
O	2084	2085	-
O	2085	2091	EP2006
O	2092	2095	and
O	2096	2105	reference
O	2106	2119	pegfilgrastim
O	2120	2124	were
O	2125	2140	therapeutically
O	2141	2151	equivalent
O	2152	2155	and
O	2156	2166	comparable
O	2167	2176	regarding
B-outcome	2177	2185	efficacy
I-outcome	2186	2189	and
I-outcome	2190	2196	safety
O	2197	2199	in
O	2200	2203	the
O	2204	2214	prevention
O	2215	2217	of
O	2218	2229	neutropenia
O	2230	2232	in
O	2233	2241	patients
O	2242	2246	with
O	2247	2252	early
O	2252	2253	-
O	2253	2258	stage
O	2259	2265	breast
O	2266	2272	cancer
O	2273	2282	receiving
O	2283	2286	TAC
O	2286	2287	.

O	2288	2291	The
O	2292	2303	granulocyte
O	2304	2310	colony
O	2310	2311	-
O	2311	2322	stimulating
O	2323	2329	factor
O	2330	2343	pegfilgrastim
O	2344	2346	is
O	2347	2353	widely
O	2354	2358	used
O	2359	2362	for
O	2363	2366	the
O	2367	2377	prevention
O	2378	2380	of
O	2381	2393	chemotherapy
O	2393	2394	-
O	2394	2401	induced
O	2402	2413	neutropenia
O	2413	2414	.

O	2415	2426	Biosimilars
O	2427	2430	are
O	2431	2440	biologics
O	2441	2445	with
O	2446	2453	similar
O	2454	2461	quality
O	2461	2462	,
O	2463	2469	safety
O	2469	2470	,
O	2471	2474	and
O	2475	2483	efficacy
O	2484	2486	to
O	2487	2488	a
O	2489	2498	reference
O	2499	2506	product
O	2507	2511	that
O	2512	2515	may
O	2516	2524	increase
O	2525	2528	the
O	2529	2542	affordability
O	2543	2545	of
O	2546	2555	treatment
O	2556	2564	compared
O	2565	2569	with
O	2570	2575	their
O	2576	2585	reference
O	2586	2595	compounds
O	2595	2596	.

O	2597	2602	There
O	2603	2606	are
O	2607	2616	currently
O	2617	2619	no
O	2620	2628	approved
O	2629	2640	biosimilars
O	2641	2643	of
O	2644	2657	pegfilgrastim
O	2658	2660	in
O	2661	2667	highly
O	2668	2677	regulated
O	2678	2685	markets
O	2685	2686	.

O	2687	2689	No
O	2690	2698	previous
O	2699	2704	phase
O	2705	2708	III
O	2709	2716	studies
O	2717	2721	have
O	2722	2726	been
O	2727	2736	performed
O	2737	2741	with
O	2742	2744	LA
O	2744	2745	-
O	2745	2751	EP2006
O	2751	2752	.

O	2753	2760	PROTECT
O	2760	2761	-
O	2761	2762	2
O	2763	2766	was
O	2767	2776	conducted
O	2777	2779	to
O	2780	2787	confirm
O	2788	2791	the
O	2792	2802	similarity
O	2803	2805	of
O	2806	2809	the
O	2810	2818	proposed
O	2819	2829	biosimilar
O	2830	2832	LA
O	2832	2833	-
O	2833	2839	EP2006
O	2840	2842	to
O	2843	2856	pegfilgrastim
O	2856	2857	.

O	2858	2868	Biosimilar
O	2869	2882	pegfilgrastim
O	2883	2884	(
O	2884	2886	LA
O	2886	2887	-
O	2887	2893	EP2006
O	2893	2894	)
O	2895	2898	may
O	2899	2906	benefit
O	2907	2915	oncology
O	2916	2924	patients
O	2925	2927	by
O	2928	2936	offering
O	2937	2946	increased
O	2947	2953	access
O	2954	2956	to
O	2957	2967	biological
O	2968	2978	treatments
O	2979	2983	that
O	2984	2987	may
O	2988	2995	improve
O	2996	3004	clinical
O	3005	3013	outcomes
O	3013	3014	.

O	3015	3019	This
O	3020	3025	means
O	3026	3030	that
O	3031	3039	patients
O	3040	3045	could
O	3046	3057	potentially
O	3058	3060	be
O	3061	3068	treated
O	3069	3085	prophylactically
O	3086	3090	with
O	3091	3100	biologics
O	3101	3107	rather
O	3108	3112	than
O	3113	3117	only
O	3118	3123	after
O	3124	3137	complications
O	3138	3142	have
O	3143	3151	occurred
O	3151	3152	.
